News from Scioderm A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jun 12, 2014, 08:00 ET

Scioderm Names Ronald Nardi, Ph.D. Chief Scientific Officer

 Scioderm, Inc. today announced the addition of Ronald Nardi, Ph.D. as the company's first chief scientific officer.   Key points:...

Apr 01, 2014, 08:00 ET

Scioderm Completes Enrollment of Phase 2b Study of SD-101, a Novel Topical Therapy for Patients with Epidermolysis Bullosa

Scioderm, Inc. today announced it has completed enrollment of its Phase 2b study (SD-003) to evaluate the safety and efficacy of SD-101, a novel...

Jan 22, 2014, 08:00 ET

Scioderm, Inc. Receives Orphan Drug Designation in the European Union for Novel Topical Therapy to Treat Epidermolysis Bullosa

 Scioderm, Inc., today announced that the European Commission (EC) has granted orphan drug designation for SD-101 for the treatment of patients...

Jan 07, 2014, 08:00 ET

Scioderm to Present at 32nd Annual J.P. Morgan Healthcare Conference

 Scioderm, Inc., today announced that Dr. Robert Ryan, President and Chief Executive Officer of Scioderm, was invited to present at the 32nd...

Jan 06, 2014, 08:00 ET

Scioderm Initiates Phase 2B Study of SD-101, A Novel Topical Therapy, for Patients with Epidermolysis Bullosa

Scioderm, Inc. today announced the initiation of a Phase 2B study designed to evaluate the efficacy and safety of SD-101, a novel topical therapy,...

Dec 17, 2013, 08:00 ET

Scioderm, Inc. receives Positive Opinion from European Orphan Medicinal Products Committee for Novel Topical Therapy to Treat Epidermolysis Bullosa

 Scioderm, Inc., today announced that the Committee for Orphan Medicinal Products (COMP) issued a positive opinion on the application for...

Dec 02, 2013, 08:00 ET

Scioderm Appoints Orphan Product Executives to Board of Directors

 Scioderm, Inc. announced the appointment of John Crowley and William Aliski to the company's Board of Directors. As Chairman & CEO of...

Oct 30, 2013, 08:00 ET

Scioderm Honored with Partners in Progress Award from DEBRA of America

 Scioderm, Inc. was honored with the Partners in Progress Award from the Dystrophic Epidermolysis Bullosa Research Association of America...

Oct 21, 2013, 08:00 ET

Scioderm's CEO Dr. Robert Ryan Appointed Member of DebRA Board

Scioderm, Inc. announced the appointment of the company's Co-Founder and CEO, Dr. Robert Ryan, to the board of directors of the Dystrophic...

Oct 14, 2013, 08:00 ET

Scioderm, Inc. to Present at BIO-Europe 2013 Conference

 Scioderm, Inc., today announced that Dr. Robert Ryan, president and chief executive officer of Scioderm, will present at the BIO-Europe...

Sep 24, 2013, 08:00 ET

Scioderm, Inc. Named a 2013 "Fierce Top 15" Company by FierceBiotech

 Scioderm, Inc., a biopharmaceutical company focused on the development of innovative therapies for treating rare diseases with high unmet...

May 03, 2013, 14:51 ET

Scioderm's SD-101 Receives Breakthrough Therapy Designation from FDA for Treatment of Epidermolysis Bullosa

Scioderm announced its investigational product SD-101 has received Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA)...

Apr 29, 2013, 08:00 ET
Scioderm Company Logo.  (PRNewsFoto/Scioderm, LLC)

Scioderm's SD-101 Receives Breakthrough Therapy Designation from FDA for Treatment of Epidermolysis Bullosa

Scioderm announced its investigational product SD-101 has received Breakthrough Therapy designation by the U.S. Food and Drug...

Apr 26, 2013, 07:12 ET
Company Logo.  (PRNewsFoto/Scioderm)

Scioderm Closes $16 Million In Series A Financing

Scioderm, a company developing novel dermatology therapeutics, today announced the completion of a Series A financing commitment totaling...

Feb 13, 2013, 19:04 ET

Scioderm's Investigational New Drug (IND) Application for SD-101 for Treatment of Epidermolysis Bullosa (EB) Allowed by the FDA

Scioderm announced that the US Food and Drug Administration (FDA) has reviewed and allowed the investigational new drug (IND) application for...

Jun 19, 2012, 16:11 ET

Scioderm Announces Positive Phase II Data of Topical SD-101 on Wound Closure and Reduction of Lesions and Blisters in Children with Epidermolysis Bullosa (EB)

Scioderm today announced results from its Phase II clinical trial investigating the efficacy, safety and tolerability of topical administration of...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge